Compound Property | Canagliflozin | NSC679207 | NSC727709 | NSC231775 | TCM21610 | TCM_Piperenol_A |
Human Intestinal Absorptiona | + | + | + | - | + | + |
P-glycoprotein Substrateb | + | - | - | + | + | + |
P-glycoprotein Inhibitor Ic | - | - | - | + | - | - |
P-glycoprotein Inhibitor IIc | - | - | - | - | + | - |
Renal Organic Cation Transporterc | - | - | - | - | - | - |
Blood-Brain Barrierd | + | + | + | + | - | - |
CYP450 2C9 Substrateb | - | - | - | - | - | - |
CYP450 2D6 Substrateb | - | - | - | - | - | - |
CYP450 3A4 Substrateb | - | + | - | - | - | - |
CYP450 1A2 Inhibitorc | - | - | + | - | - | - |
CYP450 2C9 Inhibitorc | - | - | - | - | - | - |
CYP450 2D6 Inhibitorc | - | - | - | - | - | - |
CYP450 2C19 Inhibitorc | - | - | + | - | - | - |
CYP450 3A4 Inhibitorc | - | - | - | - | - | - |
CYP450 Inhibitory Promiscuity | high | low | low | low | low | low |
hERG inhibition Ic | - | - | - | - | - | - |
hERG inhibition IIc | - | - | - | - | + | - |
Ames teste | - | - | + | - | - | - |
Carcinogenicityf | - | - | - | + | - | - |